<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362968">
  <stage>Registered</stage>
  <submitdate>3/09/2012</submitdate>
  <approvaldate>4/09/2012</approvaldate>
  <actrnumber>ACTRN12612000940875</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of  artesunate/amodiaquine and  Artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Brazzaville and Owando - Republic of the Congo</studytitle>
    <scientifictitle>Efficacy and safety of  artesunate/amodiaquine and  Artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Brazzaville and Owando - Republic of the Congo</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To assess the efficacy and safety of artesunate/amodiaquine  (4 mg/kg of artesunate, 10 mg/kg of amodiaquine, 1/day for 3 days) (oral administration) for the treatment of uncomplicated P. falciparum infections in two sites in the Republic of Congo</interventions>
    <comparator>To assess the efficacy and safety of artemether/lumefantrine
(20 mg of artemether and 120 mg of lumefantrine), 2/day for 3 days) (oral administration) for the treatment of uncomplicated P. falciparum infections  in two sites in the Republic of Congo</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent of treatment failures (early treatment failure + late clinical failure + late parasitological failure)

Enrolled patients will be assessed for parasitological (using microscopy), clinical responses during the 28 days follow-up and treatment outcomes will be classified according to the latest WHO protocol.</outcome>
      <timepoint>At day 28 following initiation of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent of adverse event will be documented. Parents or guardians of all enrolled patients will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit. When clinically indicated, patients will be evaluated and treated appropriately. All adverse events will be recorded on the case report form. 

Possible medicine related adverse effects include dizziness, itching, vomiting, abdominal pain, flatulence, headache, bodyache, diarrhoea, tinnitus and increased hair loss, macular rash, reduction in neutrophil counts and convulsions. However, it is likely that many of these effects are disease-related rather than medicine-induced.</outcome>
      <timepoint>At day 28 following initiation of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. age between 6 months and 10 yeasr;
2. mono-infection with P. falciparum detected by microscopy;
3. parasitaemia of 1000-200,000/microlitre asexual forms;
4. presence of axillary (greater or equal to) 37.5 degrees C or history of fever during the past 24 h;
5. ability to swallow oral medication;
6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
7. informed consent from a parent or guardian of children.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>10</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. presence of general danger signs or signs of severe falciparum malaria according to the definitions of WHO;
2. mixed or mono-infection with another Plasmodium species detected by microscopy;
3. presence of severe malnutrition (defined as a child whose growth standard is below 3 (z-score), having a symmetrical oedema involving at least the feet or having a mid-upper arm circumference &lt; 110 mm);
4. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
5. regular medication, which may interfere with antimalarial pharmacokinetics;
6. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Children aged 6 months to 10 years with uncomplicated malaria who meet the study inclusion criteria will be enrolled, treated on site with either artesunate/amodiaquine or artemether/lumefantrine and monitored for 28 days. The follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and laboratory examinations.</concealment>
    <sequence>N/A This surveillance study is 2 x one-arm prospective evaluation of clinical and parasitological responses to directly observed treatment for uncomplicated malaria with either artesunate/amodiaquine or artemether/lumefantrine.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Nil</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/05/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>352</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Congo</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministry of Health and Population of the Republic of Congo</primarysponsorname>
    <primarysponsoraddress>Ministere de la Sante et de la Population de la Republique du Congo
Enceint ex ORSTOM, BP 1249
Brazzaville - Congo</primarysponsoraddress>
    <primarysponsorcountry>Congo</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>World Health Organization</fundingname>
      <fundingaddress>Avenue Appia 20
1211 Geneva 27</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna</sponsorname>
      <sponsoraddress>Kinderspitalgasse 15, A-1090
Vienna</sponsoraddress>
      <sponsorcountry>Austria</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Efficacy and safety of artesunate/amodiaquine and artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in two sites in the Congo</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ministere de la Recherche Scientifique</ethicname>
      <ethicaddress>Delegation Generale de la Recherche Scientifique et Technologique
Comite d'Ethique de la Recherche en Sciences de la Sante
B.P. 2499, BRAZZAVILLE, CONGO</ethicaddress>
      <ethicapprovaldate>3/05/2012</ethicapprovaldate>
      <hrec>00000039/DGRST/CERSSA</hrec>
      <ethicsubmitdate>20/04/2012</ethicsubmitdate>
      <ethiccountry>Congo</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethical Review Committee, World Health Organization</ethicname>
      <ethicaddress>Avenune Appia 20
1211 Geneva 27</ethicaddress>
      <ethicapprovaldate>17/07/2012</ethicapprovaldate>
      <hrec>RPC509</hrec>
      <ethicsubmitdate>18/06/2012</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Mathieu Ndounga</name>
      <address>Charge de Recherche Cames
Centre d'Etudes sur les Ressources Vegetales
Groupe de Recherche Biomedicale
Enceinte ex ORSTOM, BP 1249
Brazzaville - Congo</address>
      <phone>242066977370</phone>
      <fax />
      <email>ngoualandounga@yahoo.fr</email>
      <country>Congo</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Mathieu Ndounga</name>
      <address>Charge de Recherche Cames
Centre d'Etudes sur les Ressources Vegetales
Groupe de Recherche Biomedicale
Enceinte ex ORSTOM, BP 1249
Brazzaville - Congo</address>
      <phone>242066977370</phone>
      <fax />
      <email>ngoualandounga@yahoo.fr</email>
      <country>Congo</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Alison Osborne</name>
      <address>Global Malaria Programme
World Health Organization
Avenue Appia 20
1202 Geneva</address>
      <phone>0041227912782</phone>
      <fax />
      <email>osbornea@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>